Myokardia CEO talk about its new trial data to treat heart disease

September 1, 2020

Myokardia develops therapies and treatments for inherited heart conditions, particularly hypertrophic cardiomyopathy or HCM, which affects 650,000 people in the U.S. Myokardia CEO Tassos Gianakakos joins ‘Closing Bell’ to discuss its treatments.

Read the full story here.


You can save a life …

Make a Donation or Give an AED Today